Paid Clinical Trials in Zion, IL
As of August 2026, 45 paid clinical trials are recruiting in Zion, Illinois. Compensation typically covers time, travel, and study visits, with stipends ranging from modest amounts for short outpatient studies to several thousand dollars for long or inpatient protocols.
Zion offers studies at sites including Midwestern Regional Medical Center for conditions such as Breast Cancer, Multiple Myeloma, Clear Cell Renal Cell Carcinoma, Ovarian Cancer. Both patients with specific conditions and healthy volunteers can qualify. Most trials offer free study-related medical care alongside compensation.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Trials by specialty in Zion
Trials by drug in Zion
Filter results
44 clinical trials
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3
Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients
A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
Top Research Study Locations in Zion
Researchers run research studies in Zion, IL at 17 active sites. The clinics below currently host the largest number of recruiting studies — each name is followed by the conditions they focus on most.
| Site | Specializes in | Active trials |
|---|---|---|
| Midwestern Regional Medical Center | Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Anatomic Stage I Breast Cancer AJCC v8 | 9 |
| City of Hope at Chicago | Advanced Colon Adenocarcinoma, Advanced Colorectal Adenocarcinoma, Advanced Rectal Adenocarcinoma | 6 |
| City of Hope Chicago | Breast Cancer, Metastatic, Carcinoma, Non-Small-Cell Lung, Hodgkin Lymphoma | 5 |
| City of Hope - Chicago | Hematologic Malignancies, Relapsed or Refractory Large B-cell Lymphoma, Advanced Renal Cell Carcinoma | 5 |
| City of Hope® Cancer Center Chicago | Breast Cancer, KRAS G12C Lung Cancer, Non-Small Cell Lung Cancer | 3 |
| Midwestern Regional Medical Center dba City of Hope Chicago | Metastatic Castration-resistant Prostate Cancer, Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR) | 2 |
| City of Hope - Chicago Cancer Center | Ovarian Cancer, Advanced Biliary Tract Cancer, Biliary Tract Cancer (BTC) | 2 |
| COH Chicago | Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma | 1 |
| Cancer Treatment Centers of America (CTCA) | Metastatic Non-small Cell Lung Cancer | 1 |
| City of Hope - Cancer Center Chicago | Breast Cancer | 1 |
| City of Hope Chicago Cancer Center | Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors, Glypican-3 (GPC3)-Positive Squamous Non-small Cell Lung Cancer | 1 |
| City of Hope Chicago, City of Hope Cancer Center Chicago | Clear Cell Renal Cell Carcinoma (ccRCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 1 |
| City of Hope, Chicago | Breast Cancer, Cervical Cancer, Endometrial Cancer | 1 |
| Midwestern Reg MC COH Chicago | Early Breast Cancer | 1 |
| Midwestern Regional Medical Center, City of Hope Chicago | Locally Advanced Solid Tumor | 1 |
| Midwestern Regional Medical Center, Inc. dba City of Hope Chicago | Multiple Myeloma | 1 |
| NEO-811 Chicago Site | Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic, Kidney Cancer Metastatic | 1 |
Active & Upcoming Studies in Zion (2026)
Recruiting trials in Zion grouped by therapeutic area, drawn from ClinicalTrials.gov. Each bucket shows the most recent example studies.
Cancer & tumors (40 active studies)
- Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3 · Phase 2 · City of Hope Medical Center
- Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial · Phase 3 · City of Hope Medical Center
Common conditions studied in Zion
- Breast Cancer (4 active studies)
- Multiple Myeloma (3 active studies)
- Clear Cell Renal Cell Carcinoma (2 active studies)
- Ovarian Cancer (2 active studies)
- Small Cell Lung Cancer (2 active studies)
- Adenocarcinoma of the Colon (1 active study)
Leading research sponsors in Zion
- City of Hope Medical Center
- Amgen
- NRG Oncology
- AbbVie
- Alliance for Clinical Trials in Oncology
Frequently asked questions
How many paid clinical trials are currently recruiting in Zion?
There are approximately 45 recruiting clinical trials in Zion, Illinois listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Zion pay participants?
Most recruiting trials in Zion compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Zion?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Zion?
The most common conditions under active study in Zion include Breast Cancer (4), Multiple Myeloma (3), Clear Cell Renal Cell Carcinoma (2), Ovarian Cancer (2), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Zion?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Zion on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Zion?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Zion?
Recruiting research sites in Zion include Midwestern Regional Medical Center, City of Hope at Chicago, City of Hope Chicago, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Zion right now?
The largest active categories in Zion are Cancer & tumors (40). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.